Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Chief Operating Officer | January 20, 2022 | January 24, 2022 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Chief Operating Officer | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date January 20, 2022 · Filed January 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-01-20 | Direct | 135,000 |
Reported balance
After 2022-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-20 · Grant · Acquired 135,000 · Balance 135,000 F1: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.
Rapport Therapeutics, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,914 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Sale · Disposed 7,925 · Balance 141,989 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.64 to $33.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-09-30 · Sale · Disposed 2,075 · Balance 139,914 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.64 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.64 to $33.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.64 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 00:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,075 | $33.76 | $70,042.87 |
DisclosureSEC source: 0001193125-26-410734 · ownership.xml · nonDerivative · entry 2 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,914 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.64 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7,925 | $33.04 | $261,813.47 |
DisclosureSEC source: 0001193125-26-410734 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,989 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.64 to $33.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,000 | $43.15 | $43,154.70 |
DisclosureSEC source: 0001193125-26-292546 · ownership.xml · nonDerivative · entry 4 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,914 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.81 to $43.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,308 | $42.17 | $139,505.64 |
DisclosureSEC source: 0001193125-26-292546 · ownership.xml · nonDerivative · entry 3 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,914 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.81 to $42.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,792 | $41.39 | $156,963.77 |
DisclosureSEC source: 0001193125-26-292546 · ownership.xml · nonDerivative · entry 2 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,222 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.80 to $41.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,900 | $40.09 | $76,173.66 |
DisclosureSEC source: 0001193125-26-292546 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,014 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.61 to $40.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:27 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,839 | $28.55 | $81,061.97 |
DisclosureSEC source: 0001193125-26-134684 · ownership.xml · nonDerivative · entry 2 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,914 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.42 to $28.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:27 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7,161 | $28.04 | $200,795.16 |
DisclosureSEC source: 0001193125-26-134684 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,753 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.42 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:07 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,014 | $28.93 | $58,265.02 |
DisclosureSEC source: 0001193125-26-098488 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,914 F1 · kind: Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.34 to $28.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:02 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 132,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001193125-26-037529 · ownership.xml · derivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 132,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:17 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001193125-25-303910 · ownership.xml · derivative · entry 3 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,407 Underlying: Common Stock · 5,000 shares Expires 2033-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. F3 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:17 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,000 | $30.10 | $150,486.50 |
DisclosureSEC source: 0001193125-25-303910 · ownership.xml · nonDerivative · entry 2 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,928 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:17 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | Exercise / conversionCommon Stock | 5,000 | $1.80 | $9,000.00 |
DisclosureSEC source: 0001193125-25-303910 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001839046-25-000004 · ownership.xml · derivative · entry 3 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,407 Underlying: Common Stock · 5,000 shares Expires 2033-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. F2 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,000 | $38.33 | $191,650.00 |
DisclosureSEC source: 0001839046-25-000004 · ownership.xml · nonDerivative · entry 2 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,928 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | Exercise / conversionCommon Stock | 5,000 | $1.80 | $9,000.00 |
DisclosureSEC source: 0001839046-25-000004 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantCommon Stock | 13,987 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033797 · ownership.xml · nonDerivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,928 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in two equal annual installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 129,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000950170-25-013750 · ownership.xml · derivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 129,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:43 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 88,442 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071540 · ownership.xml · derivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,442 Underlying: Common Stock · 88,442 shares Expires 2034-06-05 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 16:33 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001140361-22-002451 · form4.xml · derivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:31 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-21-041208 · form4.xml · derivative · entry 1 Gault Cheryl · CIK 0001839046 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of December 9, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.